227 related articles for article (PubMed ID: 28512676)
1. Different fermentation processes produced variants of an anti-CD52 monoclonal antibody that have divergent in vitro and in vivo characteristics.
Zhuang C; Zheng C; Chen Y; Huang Z; Wang Y; Fu Q; Zeng C; Wu T; Yang L; Qi N
Appl Microbiol Biotechnol; 2017 Aug; 101(15):5997-6006. PubMed ID: 28512676
[TBL] [Abstract][Full Text] [Related]
2. The effect of hyperosmolality application time on production, quality, and biopotency of monoclonal antibodies produced in CHO cell fed-batch and perfusion cultures.
Qin J; Wu X; Xia Z; Huang Z; Zhang Y; Wang Y; Fu Q; Zheng C
Appl Microbiol Biotechnol; 2019 Feb; 103(3):1217-1229. PubMed ID: 30554388
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology and toxicology evaluation of an anti-CD52 monoclonal antibody produced by perfusion fermentation process.
Wang Y; Zheng C; Zhuang C; Fu Q; Qin J; Zhang B; Bian Y; Qi N; Zhu J
J Ind Microbiol Biotechnol; 2021 Dec; 48(9-10):. PubMed ID: 34669957
[TBL] [Abstract][Full Text] [Related]
4. A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali L; Saxena G; Jones M; Leisegang GR; Gammon L; Gnanapavan S; Giovannoni G; Schmierer K; Baker D; Kang AS
Biotechniques; 2020 Apr; 68(4):185-190. PubMed ID: 32096651
[No Abstract] [Full Text] [Related]
5. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
6. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.
Yang WC; Lu J; Kwiatkowski C; Yuan H; Kshirsagar R; Ryll T; Huang YM
Biotechnol Prog; 2014; 30(3):616-25. PubMed ID: 24574326
[TBL] [Abstract][Full Text] [Related]
7. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.
Baker D; Ali L; Saxena G; Pryce G; Jones M; Schmierer K; Giovannoni G; Gnanapavan S; Munger KC; Samkoff L; Goodman A; Kang AS
Front Immunol; 2020; 11():124. PubMed ID: 32117274
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells.
Figueroa B; Ailor E; Osborne D; Hardwick JM; Reff M; Betenbaugh MJ
Biotechnol Bioeng; 2007 Jul; 97(4):877-92. PubMed ID: 17099908
[TBL] [Abstract][Full Text] [Related]
9. Bioreactor productivity and media cost comparison for different intensified cell culture processes.
Xu S; Gavin J; Jiang R; Chen H
Biotechnol Prog; 2017 Jul; 33(4):867-878. PubMed ID: 27977910
[TBL] [Abstract][Full Text] [Related]
10. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
[TBL] [Abstract][Full Text] [Related]
11. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar.
Rameez S; Gowtham YK; Nayar G; Mostafa SS
Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
13. Perfusion Cell Culture Decreases Process and Product Heterogeneity in a Head-to-Head Comparison With Fed-Batch.
Walther J; Lu J; Hollenbach M; Yu M; Hwang C; McLarty J; Brower K
Biotechnol J; 2019 Feb; 14(2):e1700733. PubMed ID: 29851298
[TBL] [Abstract][Full Text] [Related]
14. Cell-controlled hybrid perfusion fed-batch CHO cell process provides significant productivity improvement over conventional fed-batch cultures.
Hiller GW; Ovalle AM; Gagnon MP; Curran ML; Wang W
Biotechnol Bioeng; 2017 Jul; 114(7):1438-1447. PubMed ID: 28128436
[TBL] [Abstract][Full Text] [Related]
15. Fed-batch bioreactor performance and cell line stability evaluation of the artificial chromosome expression technology expressing an IgG1 in Chinese hamster ovary cells.
Combs RG; Yu E; Roe S; Piatchek MB; Jones HL; Mott J; Kennard ML; Goosney DL; Monteith D
Biotechnol Prog; 2011; 27(1):201-8. PubMed ID: 21312367
[TBL] [Abstract][Full Text] [Related]
16. The immunological function of CD52 and its targeting in organ transplantation.
Zhao Y; Su H; Shen X; Du J; Zhang X; Zhao Y
Inflamm Res; 2017 Jul; 66(7):571-578. PubMed ID: 28283679
[TBL] [Abstract][Full Text] [Related]
17. Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and glycosylation.
Fan Y; Jimenez Del Val I; Müller C; Wagtberg Sen J; Rasmussen SK; Kontoravdi C; Weilguny D; Andersen MR
Biotechnol Bioeng; 2015 Mar; 112(3):521-35. PubMed ID: 25220616
[TBL] [Abstract][Full Text] [Related]
18. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
19. Engineering death resistance in CHO cells for improved perfusion culture.
MacDonald MA; Nöbel M; Martínez VS; Baker K; Shave E; Gray PP; Mahler S; Munro T; Nielsen LK; Marcellin E
MAbs; 2022; 14(1):2083465. PubMed ID: 35737825
[TBL] [Abstract][Full Text] [Related]
20. Proteomic Analysis of Host Cell Protein Dynamics in the Culture Supernatants of Antibody-Producing CHO Cells.
Park JH; Jin JH; Lim MS; An HJ; Kim JW; Lee GM
Sci Rep; 2017 Mar; 7():44246. PubMed ID: 28281648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
